Equities analysts expect that Medidata Solutions Inc (NASDAQ:MDSO) will post sales of $180.06 million for the current quarter, according to Zacks. Eight analysts have issued estimates for Medidata Solutions’ earnings, with the highest sales estimate coming in at $181.02 million and the lowest estimate coming in at $179.00 million. Medidata Solutions posted sales of $155.91 million in the same quarter last year, which suggests a positive year-over-year growth rate of 15.5%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, July 23rd.
On average, analysts expect that Medidata Solutions will report full year sales of $740.14 million for the current year, with estimates ranging from $737.50 million to $742.40 million. For the next year, analysts anticipate that the business will post sales of $852.14 million, with estimates ranging from $840.00 million to $865.65 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.33. Medidata Solutions had a return on equity of 9.28% and a net margin of 7.99%. The firm had revenue of $173.50 million for the quarter, compared to analysts’ expectations of $172.12 million. During the same period last year, the business posted $0.40 earnings per share. The firm’s revenue for the quarter was up 16.3% on a year-over-year basis.
Several equities analysts recently issued reports on the company. Zacks Investment Research cut Great Portland Estates from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. TheStreet upgraded Tupperware Brands from a “d+” rating to a “c” rating in a research note on Friday, March 15th. Dougherty & Co cut Medidata Solutions from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 1st. Piper Jaffray Companies cut Medidata Solutions from an “overweight” rating to a “neutral” rating in a research note on Wednesday, June 12th. Finally, Wells Fargo & Co restated a “hold” rating on shares of Medidata Solutions in a research note on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $84.24.
MDSO traded down $0.09 during trading hours on Friday, hitting $90.96. 884,381 shares of the stock were exchanged, compared to its average volume of 2,048,634. The stock has a 50-day simple moving average of $91.11. Medidata Solutions has a 12 month low of $60.10 and a 12 month high of $98.60. The firm has a market capitalization of $5.67 billion, a PE ratio of 94.75, a price-to-earnings-growth ratio of 7.51 and a beta of 1.21. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.57 and a current ratio of 2.57.
In other Medidata Solutions news, Director Robert Taylor sold 3,294 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $90.88, for a total value of $299,358.72. Following the sale, the director now directly owns 41,757 shares of the company’s stock, valued at $3,794,876.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.70% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Quadrant Capital Group LLC increased its holdings in shares of Medidata Solutions by 126.8% during the first quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 331 shares during the period. Bronfman E.L. Rothschild L.P. increased its holdings in shares of Medidata Solutions by 26.9% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock valued at $87,000 after purchasing an additional 273 shares during the period. Canton Hathaway LLC acquired a new position in shares of Medidata Solutions during the first quarter valued at $109,000. Advisor Group Inc. grew its holdings in Medidata Solutions by 27.1% during the fourth quarter. Advisor Group Inc. now owns 2,553 shares of the company’s stock worth $173,000 after acquiring an additional 545 shares during the period. Finally, Stephens Inc. AR grew its holdings in Medidata Solutions by 8.7% during the fourth quarter. Stephens Inc. AR now owns 2,722 shares of the company’s stock worth $184,000 after acquiring an additional 218 shares during the period.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Read More: Why is total return important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.